These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Clinical translation of a PSMA inhibitor for Ferro-Flores G; Luna-Gutiérrez M; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Orocio-Rodríguez E; Davanzo J; García-Pérez FO Nucl Med Biol; 2017 May; 48():36-44. PubMed ID: 28193503 [TBL] [Abstract][Full Text] [Related]
6. Formulation and Preclinical Testing of Tc-99m-Labeled HYNIC-Glc-FAPT as a FAP-Targeting Tumor Radiotracer. Yang X; Li G; Ruan C; Hu K; Tang G Bioconjug Chem; 2023 Nov; 34(11):2133-2143. PubMed ID: 37874952 [TBL] [Abstract][Full Text] [Related]
7. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging. Ortiz-Arzate Z; Santos-Cuevas CL; Ocampo-García BE; Ferro-Flores G; García-Becerra R; Estrada G; Gómez-Argumosa E; Izquierdo-Sánchez V Nucl Med Commun; 2014 Apr; 35(4):423-32. PubMed ID: 24335877 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and Preliminary Study of Ma M; Yang G; Zhao M; Liu Y; Ge X; Jia B; Gao S Mol Pharm; 2024 Feb; 21(2):735-744. PubMed ID: 38193393 [TBL] [Abstract][Full Text] [Related]
9. Rational Design and Comparison of Novel Meng L; Fang J; Zhang J; Li H; Xia D; Zhuang R; Chen H; Huang J; Li Y; Zhang X; Guo Z J Med Chem; 2024 May; 67(10):8460-8472. PubMed ID: 38717104 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of a New Farahani AM; Maleki F; Sadeghzadeh N; Abediankenari S; Abedi SM; Erfani M Anticancer Agents Med Chem; 2020; 20(14):1695-1703. PubMed ID: 32560611 [TBL] [Abstract][Full Text] [Related]
13. A Simple Kit Formulation for Preparation and Exploratory Human Studies of a Novel Ruan Q; Zhou C; Wang Q; Kang F; Jiang Y; Li G; Feng J; Zong S; Zhang J; Wang J Mol Pharm; 2023 Jun; 20(6):2942-2950. PubMed ID: 37083360 [TBL] [Abstract][Full Text] [Related]
14. Design and biological evaluation of ⁹⁹mTc-N₂S₂-Tat(49-57)-c(RGDyK): a hybrid radiopharmaceutical for tumors expressing α(v)β(3) integrins. Ocampo-García BE; Santos-Cuevas CL; De León-Rodríguez LM; García-Becerra R; Ordaz-Rosado D; Luna-Guitiérrez MA; Jiménez-Mancilla NP; Romero-Piña ME; Ferro-Flores G Nucl Med Biol; 2013 May; 40(4):481-7. PubMed ID: 23618768 [TBL] [Abstract][Full Text] [Related]
17. Design, preparation, in vitro and in vivo evaluation of (99m)Tc-N2S2-Tat(49-57)-bombesin: a target-specific hybrid radiopharmaceutical. Santos-Cuevas CL; Ferro-Flores G; Arteaga de Murphy C; Ramírez Fde M; Luna-Gutiérrez MA; Pedraza-López M; García-Becerra R; Ordaz-Rosado D Int J Pharm; 2009 Jun; 375(1-2):75-83. PubMed ID: 19393305 [TBL] [Abstract][Full Text] [Related]
18. A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry. Qiu L; Tan H; Lin Q; Si Z; Mao W; Wang T; Fu Z; Cheng D; Shi H Mol Imaging Biol; 2020 Aug; 22(4):842-853. PubMed ID: 31741201 [TBL] [Abstract][Full Text] [Related]
19. A novel 99mTc-labeled molecular probe for tumor angiogenesis imaging in hepatoma xenografts model: a pilot study. Zhao Q; Yan P; Wang RF; Zhang CL; Li L; Yin L PLoS One; 2013; 8(4):e61043. PubMed ID: 23573294 [TBL] [Abstract][Full Text] [Related]
20. Multimeric system of 99mTc-labeled gold nanoparticles conjugated to c[RGDfK(C)] for molecular imaging of tumor α(v)β(3) expression. Morales-Avila E; Ferro-Flores G; Ocampo-García BE; De León-Rodríguez LM; Santos-Cuevas CL; García-Becerra R; Medina LA; Gómez-Oliván L Bioconjug Chem; 2011 May; 22(5):913-22. PubMed ID: 21513349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]